Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ZLAB

Zai Lab Limited ADR

Dec 13 • 04:00PM ET

26.33

Dollar change -0.39
Percentage change -1.46	%

Healthcare • Biotechnology • China • NASD

Peers: AMGN GILD BMY MRNA VRTX REGN INCY BIIB SAGE NBIX

| Held by: IBB SBIO PGJ FMED ONEQ BBP CGNG DFEM DFAE BIB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.78	Insider Own	0.22%	Shs Outstand	108.14M	Perf Week	-5.86%
Market Cap	2.85B	Forward P/E	-	EPS next Y	-1.77	Insider Trans	-22.43%	Shs Float	107.90M	Perf Month	-12.09%
Income	-270.85M	PEG	-	EPS next Q	-0.70	Inst Own	42.48%	Short Float	4.79%	Perf Quarter	27.32%
Sales	355.75M	P/S	8.00	EPS this Y	21.57%	Inst Trans	-6.73%	Short Ratio	5.32	Perf Half Y	40.88%
Book/sh	6.78	P/B	3.88	EPS next Y	34.63%	ROA	-26.70%	Short Interest	5.17M	Perf Year	-12.00%
Cash/sh	6.62	P/C	3.98	EPS next 5Y	-	ROE	-34.98%	52W Range	13.48 - 36.60	Perf YTD	-3.66%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-16.93%	ROI	-40.20%	52W High	-28.06%	Beta	0.99
Dividend TTM	-	Quick Ratio	2.87	Sales past 5Y	2095.12%	Gross Margin	63.17%	52W Low	95.33%	ATR (14)	1.45
Dividend Ex-Date	-	Current Ratio	3.01	EPS Y/Y TTM	10.91%	Oper. Margin	-95.07%	RSI (14)	42.41	Volatility	3.27% 4.80%
Employees	2175	Debt/Eq	0.19	Sales Y/Y TTM	35.01%	Profit Margin	-76.13%	Recom	1.36	Target Price	50.19
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	40.53%	Payout	-	Rel Volume	1.31	Prev Close	26.72
Sales Surprise	0.02%	EPS Surprise	94.89%	Sales Q/Q	47.72%	Earnings	Nov 12 BMO	Avg Volume	970.37K	Price	26.33
SMA20	-4.23%	SMA50	-6.58%	SMA200	26.31%	Trades		Volume	1,268,056	Change	-1.46%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-14-23	Initiated	Morgan Stanley	Overweight	$47.50
Aug-10-23	Initiated	Cantor Fitzgerald	Overweight	$70
Jan-21-22	Initiated	Macquarie	Outperform	$64
Oct-12-21	Initiated	Bernstein	Mkt Perform
Apr-28-20	Initiated	Goldman	Buy
Apr-15-20	Initiated	Guggenheim	Buy	$75
Jul-12-19	Initiated	BofA/Merrill	Buy
Jul-05-19	Initiated	Macquarie	Outperform
Jan-29-19	Initiated	Credit Suisse	Outperform
Nov-21-18	Initiated	Jefferies	Buy
Jun-21-18	Resumed	Leerink Partners	Outperform	$43
Feb-14-18	Upgrade	JP Morgan	Neutral → Overweight
Oct-16-17	Initiated	Leerink Partners	Outperform	$42
Oct-16-17	Initiated	JP Morgan	Neutral	$32

Show Previous Ratings

Dec-12-24 07:30AM	Zai Lab Announces Participation in Investor Conference in January 2025 (Business Wire)
Dec-03-24 07:17AM	Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint (TipRanks)
Dec-02-24 10:12AM	NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients (Benzinga)
07:02AM	Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer (Business Wire)
Nov-27-24 11:05PM	Zai Lab Announces the Inclusion of AUGTYRO (repotrectinib) for ROS1+ NSCLC and Other Updates in Chinas National Reimbursement Drug List (Business Wire)
06:36AM	Loading…
Nov-22-24 06:36AM	Zai Lab and Pfizer to commercialise XACDURO in China (Pharmaceutical Technology)
Nov-21-24 04:00AM	Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO (Sulbactam-Durlobactam) (Business Wire)
Nov-18-24 09:15AM	Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares (Business Wire) -6.98%
Nov-14-24 07:43PM	Zai Lab Announces Pricing of Public Offering of American Depositary Shares (Business Wire) -10.95%
Nov-13-24 04:12PM	Zai Lab Announces Proposed Public Offering of American Depositary Shares (Business Wire)
02:05AM	Zai Lab Ltd (ZLAB) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Path to Profitability (GuruFocus.com)
Nov-12-24 12:00PM	Compared to Estimates, Zai Lab Limited (ZLAB) Q3 Earnings: A Look at Key Metrics (Zacks) -6.85%
07:03AM	Zai Lab and argenx announce NMPA approval for sBLA for VYVGART Hytrulo (Pharmaceutical Technology)
06:30AM	Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates (Business Wire)
Nov-11-24 07:30AM	Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China (Business Wire)
07:30AM	Loading…
07:30AM	argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China (GlobeNewswire)
Oct-30-24 06:34AM	Zai Lab presents positive outcomes from KarXT Phase III trial for schizophrenia (Clinical Trials Arena)
Oct-29-24 07:30AM	Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China (Business Wire)
Oct-25-24 05:36AM	Zai Lab Limited (ZLAB) Moves 14.7% Higher: Will This Strength Last? (Zacks)
Oct-24-24 04:05PM	Zai Lab, A Top 6% Stock, Launched To A 16-Month High On Its 'Impressive' Results (Investor's Business Daily) +14.65%
05:15AM	ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer (Business Wire)
Oct-18-24 07:30AM	Zai Lab Announces Participation in November and December Investor Conferences (Business Wire)
Oct-17-24 08:00AM	Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 (Business Wire)
Oct-16-24 07:30AM	Zai Lab to Announce Third Quarter 2024 Financial Results and Recent Corporate Updates on November 12, 2024 (Business Wire) +5.57%
Oct-09-24 07:00AM	Zai Lab to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024 (Business Wire)
Sep-27-24 05:17AM	Zai Lab Limited (ZLAB) Surges 11.1%: Is This an Indication of Further Gains? (Zacks)
Sep-17-24 01:32PM	Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024 (Business Wire)
Aug-29-24 04:09PM	Zai Lab Limited (ZLAB): Top ADR Stock According to Hedge Funds (Insider Monkey)
Aug-27-24 08:30AM	Zai Lab to Present Preliminary Data From Phase 1 Trial of ZL-1218, an Investigational Anti-CCR8 Antibody for the Treatment of Advanced Solid Tumors, at ESMO Congress 2024 (Business Wire)
Aug-22-24 07:30AM	Zai Lab Announces Participation in September Investor Conferences (Business Wire)
04:05PM	Loading…
Aug-06-24 04:05PM	Zai Lab Announces Second Quarter 2024 Financial Results and Recent Corporate Updates (Business Wire) -8.06%
Jul-26-24 08:04AM	Trade of the Day: Zai Lab (ZLAB) Stock Is a Possible Hidden Gem (InvestorPlace)
Jul-17-24 06:32AM	China NMPA approves Zai Lab-argenxs efgartigimod alfa for gMG (Pharmaceutical Technology)
Jul-16-24 12:30AM	argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China (GlobeNewswire)
12:15AM	Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China (Business Wire)
Jul-15-24 02:53PM	Zai Lab-Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy (Business Wire)
Jul-10-24 07:30AM	Zai Lab to Announce Second Quarter 2024 Financial Results and Recent Corporate Updates on August 6, 2024 (Business Wire)
Jun-27-24 07:00PM	Insider Selling: Chairperson & CEO Ying Du Sells Shares of Zai Lab Ltd (ZLAB) (GuruFocus.com)
Jun-11-24 04:05PM	Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D (Business Wire)
Jun-04-24 11:59AM	Qiming's Nisa Leung Made the 2024 Forbes Midas List (PR Newswire) +7.17%
May-27-24 09:09AM	Here's Why Zai Lab Limited (ZLAB) Fell in Q1 (Insider Monkey)
May-23-24 08:52AM	Zai Lab doses first subject in Phase II plaque psoriasis treatment trial (Clinical Trials Arena) -5.46%
May-22-24 07:30AM	Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis (Business Wire)
May-20-24 06:31AM	Chinas NMPA approves Zai Labs XACDURO NDA for pneumonia (Pharmaceutical Technology) +7.42%
04:06AM	Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment (MT Newswires)
12:21AM	Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China (Business Wire)
May-17-24 02:36AM	Insider Sale: Chief Legal Officer of Zai Lab Ltd (ZLAB) Sells Shares (GuruFocus.com)
May-16-24 07:30AM	Zai Lab Announces Participation in May and June Investor Conferences (Business Wire)
May-14-24 08:41AM	Zai Lab's Supplemental Application for Autoimmune Disease Treatment Accepted by China Regulator (MT Newswires)
07:30AM	Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China (Business Wire)
May-13-24 11:42AM	BMS and Zai Labs Augtyro gains NMPA approval to treat NSCLC (Pharmaceutical Technology) +7.17%
08:51AM	Zai Lab Says China Approves New Drug Application for Lung Cancer Treatment Augtyro (MT Newswires)
May-12-24 08:20PM	Zai Lab Announces Approval of AUGTYRO (repotrectinib) for Patients with ROS1-positive NSCLC by Chinas NMPA (Business Wire)
May-10-24 05:14PM	Zai Lab Limited (NASDAQ:ZLAB) Q1 2024 Earnings Call Transcript (Insider Monkey) +7.17%
May-09-24 01:17PM	Zai Lab's Shares Rise After Q1 Beat (MT Newswires) +26.80%
12:15PM	Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036 (PR Newswire)
07:29AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
May-08-24 09:57PM	ZLAB Stock Earnings: Zai Lab Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:05PM	Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates (Business Wire)
Apr-15-24 07:30AM	Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024 (Business Wire)
Apr-11-24 07:30AM	Zai Lab Statement on Executive Management Teams Agreement on Share Activities (Business Wire)
Apr-02-24 07:30AM	Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs (Business Wire)
Apr-01-24 07:30AM	Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic... (Business Wire)
Mar-27-24 09:29AM	Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer (Business Wire)
Mar-20-24 04:30PM	Shhh! 7 Small-Cap Stocks That Can Double by 2025 (InvestorPlace) -5.80%
Mar-19-24 07:01PM	Chief Legal Officer Edmondson Frazor Titus III Sells 10,000 Shares of Zai Lab Ltd (ZLAB) (GuruFocus.com)
Mar-13-24 07:05PM	Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors (Business Wire)
Mar-06-24 04:01PM	Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC) (Business Wire)
07:30AM	Zai Lab Announces Participation in March Investor Conference (Business Wire)
Mar-01-24 10:12AM	argenx SE (NASDAQ:ARGX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 08:51AM	Zai Lab Limited (NASDAQ:ZLAB) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 04:38PM	Zai Lab Ltd (ZLAB) Reports 25% Year-Over-Year Revenue Growth in Full-Year 2023 Financial Results (GuruFocus.com) +7.15% -7.51%
04:05PM	Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates (Business Wire)
Feb-25-24 09:32PM	Qiming Venture Partners Becomes a UN PRI Signatory (PR Newswire)
Jan-25-24 04:15PM	Zai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024 (Business Wire)
Jan-10-24 05:12PM	Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC (Business Wire)
Jan-04-24 07:02PM	Zai Lab Ltd Chairperson & CEO Ying Du Sells 8,380 Shares (GuruFocus.com)
Dec-22-23 12:00PM	What Makes Zai Lab Limited Unsponsored ADR (ZLAB) a New Buy Stock (Zacks)
Dec-19-23 07:30AM	Zai Lab Announces Participation in January Investor Conference (Business Wire)
Dec-13-23 08:53AM	Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA in China's National Reimbursement Drug List (GlobeNewswire) +11.85%
Dec-12-23 11:10PM	Zai Lab Announces the First Listing of VYVGART (efgartigimod alfa injection) and Other Updates in Chinas National Reimbursement Drug List (Business Wire)
Nov-23-23 09:42AM	14 Best Short-Term Stocks to Invest In (Insider Monkey)
Nov-09-23 02:39PM	Zai Lab Limited (NASDAQ:ZLAB) Q3 2023 Earnings Call Transcript (Insider Monkey) -6.16%
Nov-07-23 04:05PM	Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates (GlobeNewswire) +6.00%
Oct-26-23 07:30AM	Zai Lab Announces Participation in November Investor Conferences (GlobeNewswire)
Oct-18-23 07:30AM	Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7, 2023 (GlobeNewswire)
Oct-17-23 08:25AM	Ultragenyx (RARE) Surges 10.3%: Is This an Indication of Further Gains? (Zacks)
Oct-14-23 01:15PM	13 Stocks to Buy with Exponential Growth (Insider Monkey)
Sep-21-23 04:48PM	Betting Big: 3 Tech Stocks Primed for a Breakout (InvestorPlace) -5.55%
Sep-18-23 07:30AM	Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China (GlobeNewswire)
Sep-05-23 11:16AM	Why Shares of Zai Lab Limited Were Jumping on Tuesday (Motley Fool) +9.73%
09:23AM	Seagen's (SGEN) Late-Stage Cervical Cancer Study Meets Goals (Zacks)
Aug-31-23 09:16AM	Zai Lab (ZLAB) Up on Breakthrough Therapy Tag for Oncology Drug (Zacks)
Aug-30-23 07:30AM	Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China (GlobeNewswire) +11.39%
Aug-29-23 07:38AM	Zai Lab Announces Participation in September Investor Conferences (GlobeNewswire)
Aug-10-23 10:12AM	Penn downgraded, Roblox upgraded: Wall Street's top analyst calls (The Fly)
Aug-07-23 04:05PM	Zai Lab Announces Second Quarter 2023 Financial Results and Corporate Updates (GlobeNewswire) -8.58%
Jul-28-23 03:57PM	12 Stocks with Biggest Upside Potential According to Analysts (Insider Monkey) +5.32%
Jul-20-23 07:30AM	Zai Lab to Announce Second Quarter 2023 Financial Results and Corporate Updates on August 7, 2023 (GlobeNewswire)
Jul-19-23 07:30AM	JAMA Oncology Publishes Data from Zai Lab Study Demonstrating Significant Reduction in Disease Progression or Death with ZEJULA (Niraparib) Maintenance Therapy in Broad Population of Advanced Ovarian Cancer Patients (GlobeNewswire)

Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chen Yajing	Chief Financial Officer	Nov 04 '24	Sale	30.66	167	5,121	15,494	Nov 05 04:31 PM
Chen Yajing	Officer	Nov 04 '24	Proposed Sale	30.66	167	5,121		Nov 04 03:37 PM
Chen Yajing	Chief Financial Officer	Oct 02 '24	Sale	25.40	301	7,645	15,161	Oct 03 04:14 PM
Chen Yajing	Officer	Oct 02 '24	Proposed Sale	25.40	301	7,645		Oct 02 03:06 PM
Reinhart Harald	Former Officer	Sep 26 '24	Proposed Sale	22.00	60,000	1,320,000		Sep 26 03:52 PM
Reinhart Harald	Former Officer	Sep 19 '24	Proposed Sale	21.16	70,000	1,481,095		Sep 19 04:55 PM
GAYNOR RICHARD	Director	Sep 03 '24	Sale	19.50	2,500	48,750	46,568	Sep 05 04:13 PM
GAYNOR RICHARD	Director	Sep 03 '24	Proposed Sale	19.50	2,500	48,750		Sep 03 12:12 PM
Edmondson Frazor Titus III	Chief Legal Officer	Aug 19 '24	Sale	16.95	1,924	32,619	28,872	Aug 20 04:42 PM
Smiley Joshua L	See Remarks	Aug 16 '24	Sale	16.67	4,352	72,561	43,232	Aug 19 04:45 PM
Edmondson Frazor Titus III	Officer	Aug 19 '24	Proposed Sale	16.95	1,924	32,620		Aug 19 03:16 PM
Chen Yajing	Chief Financial Officer	Aug 15 '24	Sale	16.06	422	6,779	14,542	Aug 16 04:38 PM
Smiley Joshua L	Officer	Aug 16 '24	Proposed Sale	16.67	4,352	72,560		Aug 16 03:14 PM
Chen Yajing	Officer	Aug 15 '24	Proposed Sale	16.06	422	6,779		Aug 15 03:37 PM
Amado Rafael	See Remarks	Aug 12 '24	Sale	16.20	3,115	50,463	20,417	Aug 14 04:18 PM
Amado Rafael	Officer	Aug 12 '24	Proposed Sale	16.20	3,115	50,463		Aug 12 11:30 AM
Lis William	Director	Jul 01 '24	Sale	17.32	10,397	180,085	53,089	Jul 03 02:04 PM
Du Ying	Chairperson & CEO	Jul 01 '24	Sale	17.48	7,013	122,573	1,081,910	Jul 02 04:30 PM
Reinhart Harald	See Remarks	Jun 26 '24	Sale	17.90	7,431	133,022	62,619	Jun 27 04:09 PM
Edmondson Frazor Titus III	Chief Legal Officer	Jun 26 '24	Sale	17.90	5,062	90,615	25,946	Jun 27 04:09 PM
Du Ying	Chairperson & CEO	Jun 26 '24	Sale	17.90	23,939	428,532	1,142,833	Jun 27 04:08 PM
Chen Yajing	Chief Financial Officer	Jun 26 '24	Sale	17.90	2,154	38,559	13,714	Jun 27 04:08 PM
Edmondson Frazor Titus III	Chief Legal Officer	May 14 '24	Sale	21.33	10,000	213,346	16,408	May 16 04:52 PM
Smiley Joshua L	See Remarks	May 13 '24	Buy	21.40	3,000	64,200	31,684	May 15 04:03 PM
Smiley Joshua L	See Remarks	Apr 03 '24	Option Exercise	15.90	7,145	113,606	30,672	Apr 05 05:48 PM
Smiley Joshua L	See Remarks	Apr 04 '24	Sale	15.67	1,988	31,158	28,684	Apr 05 05:48 PM
Reinhart Harald	See Remarks	Apr 03 '24	Option Exercise	15.90	5,270	83,793	53,905	Apr 05 05:48 PM
Reinhart Harald	See Remarks	Apr 04 '24	Sale	15.67	2,105	32,992	51,800	Apr 05 05:48 PM
Edmondson Frazor Titus III	Chief Legal Officer	Apr 03 '24	Option Exercise	15.90	5,031	79,993	27,652	Apr 05 05:48 PM
Edmondson Frazor Titus III	Chief Legal Officer	Apr 04 '24	Sale	15.67	1,244	19,497	26,408	Apr 05 05:48 PM
Chen Yajing	Chief Financial Officer	Apr 03 '24	Option Exercise	15.90	2,500	39,750	10,463	Apr 05 05:47 PM
Chen Yajing	Chief Financial Officer	Apr 04 '24	Sale	15.67	845	13,244	9,618	Apr 05 05:47 PM
Amado Rafael	See Remarks	Apr 03 '24	Option Exercise	15.90	5,391	85,717	25,484	Apr 05 05:47 PM
Amado Rafael	See Remarks	Apr 04 '24	Sale	15.67	1,952	30,594	23,532	Apr 05 05:47 PM
Edmondson Frazor Titus III	Chief Legal Officer	Apr 01 '24	Option Exercise	16.72	3,501	58,537	23,506	Apr 03 09:54 PM
Edmondson Frazor Titus III	Chief Legal Officer	Apr 02 '24	Sale	16.15	885	14,294	22,621	Apr 03 09:54 PM
Reinhart Harald	See Remarks	Apr 01 '24	Option Exercise	16.72	4,348	72,699	50,408	Apr 03 09:45 PM
Reinhart Harald	See Remarks	Apr 02 '24	Sale	16.15	1,773	28,636	48,635	Apr 03 09:45 PM
Du Ying	Chairperson & CEO	Apr 01 '24	Option Exercise	16.72	14,200	237,424	1,113,759	Apr 03 09:44 PM
Du Ying	Chairperson & CEO	Apr 02 '24	Sale	16.15	5,787	93,466	1,107,972	Apr 03 09:44 PM
Chen Yajing	Chief Financial Officer	Apr 01 '24	Option Exercise	16.72	1,500	25,080	8,482	Apr 03 09:44 PM
Chen Yajing	Chief Financial Officer	Apr 02 '24	Sale	16.15	519	8,382	7,963	Apr 03 09:44 PM
Amado Rafael	See Remarks	Mar 15 '24	Sale	18.86	2,544	47,980	20,093	Mar 19 04:12 PM
Edmondson Frazor Titus III	Chief Legal Officer	Mar 15 '24	Sale	18.71	10,000	187,127	20,005	Mar 19 04:12 PM
Smiley Joshua L	See Remarks	Mar 01 '24	Buy	20.83	3,000	62,490	23,527	Mar 04 04:28 PM
Amado Rafael	See Remarks	Jan 02 '24	Sale	26.30	19,363	509,169	22,637	Jan 03 07:26 PM
Du Ying	Chairperson & CEO	Jan 03 '24	Sale	26.12	8,380	218,902	1,133,450	Jan 03 07:25 PM
Reinhart Harald	See Remarks	Jan 03 '24	Sale	26.12	4,803	125,464	46,060	Jan 03 07:25 PM
Edmondson Frazor Titus III	Chief Legal Officer	Jan 03 '24	Sale	26.12	4,803	125,464	30,005	Jan 03 07:25 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ZLAB

Zai Lab Limited ADR

Upgrade your FINVIZ experience